

Global Personalized Medicine Market – Types, Technologies and Applications

"The report reviews, analyzes and projects the global market for Personalized Medicine for the period 2015-2024. The market for personalized medicine types analyzed in this study includes Personalized Medicine Diagnostics, Personalized Medical Care, Personalized Medicine Therapeutics and Personalized Nutrition & Wellness. The report analyzes the market for personalized medicine technologies comprising Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies. Personalized Medicine applications' market explored in this study include Oncology, Central Nervous System (CNS), Immunology, Respiratory and Other Applications".

Published: October 2018 Report Code: BT013

Pages: 386 Charts: 171


Price: \$4050 Single User License, \$6750 Enterprise License

Report Synopsis

Personalized medicine has a huge potential in leading the healthcare industry with drastic changes with a key focus on diseases understanding & management integrated with advanced analytics, patient data, customized medicines and other possibilities. Personalized Medicine will transform the entire pharmaceutical value chain, from early development to companies' go-to-market models, and the next five years will be a crucial window for pharmaceutical companies to capitalize on this promise. Companies simply cannot sit on the sidelines during this period. Instead, they need to take risks and more actively engage with stakeholders throughout the healthcare ecosystem. However, there seems to be some challenges such as an unclear regulatory framework, insufficient access to high-quality data, data privacy issues and lack of standards.

Global Personalized Medicine market is expected to witness a robust CAGR of over 11% during the 2017-2024 analysis period and projected to touch US\$194.4 billion by 2024 from an estimated US\$92.4 billion in 2017. By application, Oncology is estimated the largest market accounting for about 30% throughout the analysis period.





Source: Industry Experts, Inc. http://industry-experts.com

Research Findings & Coverage

- The global personalized medicine market is explored in this study with respect to product types, technologies and major applications
- The exclusive analysis has been carried out for each product type, technology and major application of personalized in all major regions for the analysis period

- Precision Medicine Enhanced through Artificial Intelligence and Blockchain
- Personalized Cancer Therapy Gets a Boost from Patient-Derived Tumor Organoids
- Future of Personalized Medicine Linked to Microbiomics
- Key business trends focusing on product innovations/developments, M&As,
 JVs and other recent industry developments
- Major companies profiled 73
- The industry guide includes the contact details for 115 companies

Product Outline

The report analyzes the market for key types of Personalized Medicine including:

- Personalized Medicine Diagnostics
- Personalized Medical Care
- Personalized Medicine Therapeutics
- Personalized Nutrition & Wellness

The study reviews global market for Personalized Medicine technologies comprising:

- Pharmacogenomics
- Point-of-Care Testing
- Stem Cell Therapy
- Pharmacoproteomics
- Pharmacogenetics
- Other Technologies

The following application areas of Personalized Medicine are analyzed in this report:

- Oncology
- Central Nervous System (CNS)
- Immunology
- Respiratory
- Other Applications

Analysis Period, Units and Growth Rates

 The report reviews, analyzes and projects the global Personalized Medicine market for the period 2015-2024 in terms of market value in US\$ and the compound annual growth rates (CAGRs) projected from 2017 through 2024

Geographic Coverage

- North America (The United States, Canada and Mexico)
- Europe (France, Germany, Italy, the United Kingdom and Rest of Europe)
- Asia-Pacific (China, India, Japan and Rest of Asia-Pacific)
- South America (Argentina, Brazil and Rest of South America)
- Rest of World



SAMPLE COMPANY PROFILE

AGILENT TECHNOLOGIES, INC. (UNITED STATES)

5301 Stevens Creek Blvd Santa Clara, CA 95051 Phone: +1 408-345-8886, Fax: +1 408-345-8474

Website: www.agilent.com

Business Overview

Established in 1999 and headquartered in California, Agilent Technologies Inc., (Agilent) is a global leader in life sciences, diagnostic and application markets. The company offers various scientific instruments, services & solutions, consumables for customers worldwide in research & diagnostics laboratories and analytical arena. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. Agilent is a key player in molecular diagnostics offering solutions on human genetics, parental testing, and oncology. The company develops molecular Next-Generation Sequencing (NGS) solutions, assays and products incompliance with international quality standards. The company offers wide solutions portfolios for pharmaceutical industry from disease research and drug discovery to drug development, manufacturing and quality control. The start-to-finish solution set means customers can get products to market faster. Agilent offers head start solutions to doctors in the fight against cancer and other diseases. The solutions help pathology laboratories deliver fast, accurate information to the doctors, hospitals and medical centers they serve. The company's products help medical professionals make more accurate diagnoses so patients can receive the most effective therapies. Agilent life sciences and diagnostics research is performed at top-tier universities, with funding from governments worldwide. The company helps these researchers learn more about cancer, cardiovascular diseases, diabetes, Alzheimer's, Parkinson's, autism and other ailments. The instruments, software and sample preparation solutions help scientists conduct faster, more accurate research. Agilent's key product and solution portfolio includes Chromatography, Mass Spectrometry, Spectroscopy, Capillary Electrophoresis, Certified Pre-Owned Instruments, Columns, Parts & Supplies, Instrument Repair, Sample Preparation, Cell Analysis, Automated Electrophoresis, Microarray Solutions, Gene Expression Microarrays, miRNA Microarrays, CGH & CGH+SNP Microarrays, Mutagenesis & Cloning, FISH Probes and others. The company employs over 14,200 people operating in more than 110 countries.

Divisional Analysis

Life Sciences and Applied Markets

The Life Sciences and Applied Markets division is engaged in providing products such as liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.


.....more

SAMPLE TABLE/CHART

Glance at 2017 Global Personalized Medicine Market Share (%) by Geographic Region - North America, Europe, Asia Pacific, South America and Rest of World



North American Personalized Medicine Market Analysis (2015-2024) by Technology - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies in USD Million



KEY PLAYERS PROFILED

- Abbott Laboratories, Inc.
- Agilent Technologies, Inc.
- Amgen, Inc.
- Astellas Pharma, Inc.
- Astrazeneca Plc
- Bayer AG
- Celgene Corporation
- Glaxosmithkline Plc
- Illumina, Inc.
- Johnson & Johnson
- Laboratory Corporation of America
- Merck KGaA
- Novartis AG
- Roche Holding AG
- Siemens AG
- Takeda Pharmaceutical Company Limited

.....more



TABLE OF CONTENTS

| PART A: GLOBAL MARKET PERSPECTIVE 1 |
|--|
| 1. INTRODUCTION1 |
| 1.1 Product Outline5 |
| 1.1.1 The Human Genome: What is It?6 |
| 1.1.2 Personalized Medicine Defined7 |
| 1.1.3 Personalized Medicine's Influence on Large |
| Scale Studies |
| 1.1.4 Gazing into the Crystal Ball: What the Future Holds for Personalized Medicine9 |
| 1.1.5 Ramifications of Personalized Medicine for |
| Healthcare Systems |
| 1.1.5.1 Pharmaceutical Industry |
| 1.1.5.2 Diagnostics Industry |
| 1.1.5.3 Insurers |
| 1.1.5.4 Physicians |
| 1.1.5.5 Government Agencies |
| 1.1.5.6 Patients |
| 1.1.6 Personalized Medicine Product Types11 |
| 1.1.6.1 Personalized Medicine Diagnostics |
| 1.1.6.1.1 Genetic Testing |
| 1.1.6.1.2 Direct-to-consumer Diagnostics |
| 1.1.6.2.1 Personalized Medicine Will Transform the |
| Pharmaceutical and Healthcare Industries |
| 1.1.6.2.2 Personalized Medical Devices |
| 1.1.6.2.3 Genomic Medicine |
| 1.1.6.3 Personalized Medical Care16 |
| 1.1.6.3.1 Telemedicine |
| 1.1.6.3.2 Health Information Technology |
| 1.1.6.3.3 Diseases Management |
| 1.1.6.4 Personalized Nutrition & Wellness |
| 1.1.7 Personalized Medicine Technologies |
| 1.1.7 Personalized Medicine reciniologies |
| 1.1.7.1.1 Drug Metabolism |
| 1.1.7.1.2 Applications |
| 1.1.7.2 Point-of-Care Testing21 |
| 1.1.7.2.1 Tests that are Most Apt for Specific |
| Scenarios |
| 1.1.7.2.2 Advantages |
| 1.1.7.3 Stem Cell Therapy |
| 1.1.7.3.1 Treatment with Stem Cells |
| 1.1.7.3.3 Future Treatments |
| 1.1.7.4 Pharmacoproteomics |
| 1.1.7.5 Pharmacogenetics |
| 1.1.7.5.1 Prediction of Drug-Drug Interactions 26 |
| 1.1.7.5.2 Integration of Pharmacogenetics with the |
| Healthcare System27 |
| 1.1.7.5.3 Pharmacogenetic Tests |
| 1.1.7.6 Other Personalized Medicine Technologies . 28 |
| 1.1.7.6.1 Biochips |
| 1.1.7.6.1.2 Protein Biochip Array and Other |
| Microarray Technologies |
| 1.1.7.6.1.3 Biochips Applications: Ranging from |
| Diagnostics to Personalized Medicine30 |
| 1.1.7.6.2 Metabolomics |
| 1.1.7.6.2.1 Analytical Technologies31 |
| 1.1.7.6.2.1.1 Separation Methods |
| Gas Chromatography (GC) |
| High Performance Liquid Chromatography (HPLC) 32 |
| Capillary Electrophoresis (CE) 32 1.1.7.6.2.1.2 Detection Methods 32 |
| Mass Spectrometry (MS) |
| Nuclear Manastic Bases and (NMAR) Construction 32 |

| 1.1.7.6.2.2 Major Application Areas | |
|---|-----|
| 1.1.7.6.3 Molecular Diagnostics | 33 |
| 1.1.7.6.3.1 Molecular Diagnostics for Personalized | |
| Medicine | |
| 1.1.7.6.4 Pharmacodynamics | |
| 1.1.7.6.6 SNP Genotyping | |
| 1.1.7.6.6.1 Core Labs | |
| 1.1.7.6.6.2 Hybridization-Based Methods | |
| 1.1.7.6.6.3 Enzyme-Based Methods | |
| 1.1.7.6.6.4 Other Post-Amplification Methods Based | |
| on Physical Properties of DNA | 37 |
| 1.1.8 Personalized Medicine Applications | |
| 1.1.8.1 Oncology | |
| 1.1.8.1.1 Personalized Medicine in Cancer Treatment | |
| 1.1.8.1.1.1 The Promise of Personalized Medicine | 38 |
| 1.1.8.1.1.2 Personalized Medicine as a Treatment | |
| Approach | |
| 1.1.8.1.1.3 Personalized Medicine Does Not Yet App to Everyone | |
| 1.1.8.1.1.4 Personalized Medicine Research Moving | |
| Forward | |
| 1.1.8.1.2 Examples of personalized medicine | |
| 1.1.8.2 Central Nervous System (CNS) | |
| 1.1.8.2.1 Personalized Medicine in Brain Metastase | |
| A Plea for More Translational Studies | 40 |
| 1.1.8.3 Immunology | 41 |
| 1.1.8.3.1 Clinical Immunology | 41 |
| 1.1.8.4 Respiratory | 43 |
| 1.1.8.4.1 Respiratory System: Facts, Function and | |
| Diseases | |
| 1.1.8.4.2 Diseases of the respiratory system 1.1.8.5 Other Applications of Personalized Medicine | |
| 1.1.8.5.1 Psychiatry | |
| 1.1.8.5.2 Antiviral Therapy | |
| 1.1.8.5.3 Diabetes | |
| 1.1.8.5.4 Coagulation and blood transfusion safety | |
| 2. KEY MARKET TREDNS | |
| 2.1 Precision Medicine Enhanced through Artificial | 40 |
| Intelligence and Blockchain | 48 |
| Artificial Intelligence for Genome Sequencing | |
| 2.2 Personalized Cancer Therapy Gets a Boost from | |
| Patient-Derived Tumor Organoids | 51 |
| 2.3 Patient-Derived Organoid Models of Bladder | |
| Cancer Help in Determining Tumor Evolution and | |
| Drug Response | |
| 2.4 Personalized Immunotherapy in Cancer Improve | |
| through Tumor Organoids | 53 |
| 2.5 Future of Personalized Medicine Linked to | г 4 |
| Micorbiomics | 54 |
| Personalized Medicine | 56 |
| | |
| 3. KEY GLOBAL PLAYERS | |
| Abbott Molecular, Inc. (United States) | |
| Agilent Technologies, Inc. (United States) | 60 |
| Dako A/S (Denmark) | |
| Amgen, Inc. (United States) | |
| Astrazeneca Plc (United Kingdom) | |
| Astellas Pharma, Inc. (Japan) | |
| Bayer Ag (Germany) | 71 |
| Bayer Healthcare Pharmaceuticals, Llc (Germany) | |
| Celgene Corporation (United States) | |
| Illumina, Inc. (United States) | .75 |
| Johnson & Johnson (United States) | |
| | 70 |

| | Merck Kgaa (Germany) Sigma-Aldrich Corporation (United States) Novartis Ag (Switzerland) | 8: |
|----|---|------|
| | Roche Holding Ag (Switzerland) | 84 |
| | Roche Diagnostics Corporation (United States) Siemens Ag (Germany) | |
| | Siemens Healthcare GmbH (Germany) | . 86 |
| | Siemens Healthcare Diagnostics, Inc. (United States) Takeda Pharmaceutical Company Limited (Japan) | |
| 4. | KEY BUSINESS AND PRODUCT TRENDS | |
| | Almac Discovery Ltd, Elasmogen Ltd and Innovate UK | . 0: |
| | Form an Alliance on VNAR Based Oncology Platform | 89 |
| | Haplogen GmbH and Bayer AG Join Hands for Drug Discovery and Development | 90 |
| | Amgen, Inc and Cedars-Sinai Medical Center Collaborat | |
| | on Research Programs in Personalized Medicine LEO Pharma A/S to Acquire Bayer's Dermatology Unit | |
| | Biocartis Group NV Introduces Innovative Idylla™ MSI | |
| | Assay | 9: |
| | Development Using Human Genetics | |
| | MD Anderson Cancer Center and Bayer AG Collaborate Cancer Treatment Medicine | |
| | FDA Approval for Beckman Coulter's Troponin (hsTnl) | , |
| | Assays Roche and Foundation Medicine, Inc Enter into | 92 |
| | Agreement | |
| | LabCorp and Unilabs Join Hands on Personalized Medic Offering | |
| | Abbott Develops Deep Brain Stimulation System, Life- | |
| | Changing Treatment | |
| | Test | 93 |
| | Myriad Genetics Inc to Acquire Counsyl, Inc Owlstone Medical Ltd Enters into Collaboration with | 94 |
| | AstraZeneca Plc | 94 |
| | Boehringer Ingelheim GMBH and OSE Immunotherapeutics SA Enter into Partnership | Q, |
| | PerkinElmer, Inc and Helix Enter into Agreement on | |
| | Exome-based Personal Genomics Daiichi Sankyo Co., Ltd and DarwinHealth Collaboration | |
| | Novel Cancer Drug Development | |
| | Roche, Foundation Medicine Inc, and DIAN Diagnostics Collaborate to Progress Personalized Cancer Care in China | 0 |
| | Loxo Oncology and Illumina, Inc Collaborate on Next- | . 51 |
| | Generation Sequencing-Based Pan-Cancer Companion Diagnostics | 04 |
| | Vineti and Deloitte Work on Personalized Medicine | . 50 |
| | Development | |
| | Siemens Healthineers Launches 1.5T MRI Scanner | 9. |
| | Magnetom Sola | 9 |
| | Abbott Laboratories Inc and SurModics, Inc Enter into Agreement on Next-Generation Drug-Coated Balloon | . 98 |
| | Almac Diagnostics and DNAnexus Join Forces | |
| | Roche Acquires Flatiron Health, Inc | 99 |
| | AstraZeneca Plc | |
| | BIOCRATES Life Sciences AG Acquires Metanomics Heal GmbH | |
| | Roche and GE Healthcare Enter into Partnership on | |
| | Individualized Oncology and Critical Care Treatment : Illumina, Inc and KingMed Diagnostics Agree on Next- | 100 |
| | Generation Sequencing (NGS) Technology | |
| | Bayer AG Receives Chinese Food and Drug Administrati | |
| | (CFDA) Approval for Stivarga® (Regorafenib) Tablets for the Second-line Treatment of Patients with Hepatocellu | |
| | Carcinoma (HCC) | |
| | Fortuna Fix Inc Raises Funds for Stem Cell Treatments for Parkinson's Disease and Spinal Cord Injuries | |
| | Bayer AG and Loxo Oncology Inc to Develop and | |
| | Commercialize Two Novel Oncology Therapies | 10: |
| | | 101 |



Global Personalized Medicine Market – Types, Technologies and Applications October 2018 | 386 Pages | 171 Charts | Price \$4050

| Inc Agree on Nonalcoholic Steatohepatitis (NASH) Treatment Development102 |
|--|
| Laboratory Corporation of America® Holdings Launch PD- |
| L1 IHC 28-8 PharmDx Assay102 |
| Laboratory Corporation of America Holdings Company |
| Enters into Partnership with MedReleaf Corp103 |
| Siemens Healthineers Develops Nexaris Therapy Suite .103 |
| Abbott Laboratories, Inc Receives FDA 510(k) Clearance |
| for Alinity™ CI-Series Instruments |
| The National Institutes of Health (NIH) and Bio- Pharmaceutical Companies Collaborate on Personalized |
| Medicine Approach to Cancer Care104 |
| Myriad Genetics, Inc Offers Personalized Medicine Tests |
| for Breast Cancer104 |
| Abbott Laboratories Inc, Acquires Alere, Inc105 |
| Center for Molecular Medicine of the Austrian Academy of |
| Sciences (CeMM) Develops Cancer Immunotherapies and |
| Advance Personalized Medicine |
| Bristol-Myers Squibb and Daiichi Sankyo Co., Ltd Enter into Clinical Collaboration in HER2-Expressing Breast and |
| Bladder Cancers105 |
| AstraZeneca plc and Takeda Pharmaceutical Company |
| Limited today announce Partnership106 |
| Amgen's Therapy Vectibix® (panitumumab) Receives FDA |
| Approval106 |
| Blue Shield of California Develops Agendia's |
| MammaPrint® Technology |
| Baxter International, Inc and Dorizoe Lifesciences Limited |
| Enter into Agreement |
| AG Develop AbsoluteIDQ® p400 HR kit107 |
| Agilent Technologies Inc, Expands the Usage of Dako PD- |
| L1 IHC 28-8 PharmDx Test in Europe108 |
| Abbott Laboratories Inc Unveils Nutrition Drinks108 |
| Myriad Genetics Inc and BeiGene, Ltd Collaborate on |
| Companion Diagnostics Development for Personalized |
| Medicine Drive |
| Illumina, Inc Reveals Somatic Genetic Alterations to |
| Clinical Interpretation of Variants in Cancer (CIViC)109 |
| Alman Diagraphics and FORTC Initia Farmer on Tourse |
| Almac Diagnostics and EORTC Join Forces on Tumor Molecular Profiling |
| Molecular Profiling109 |
| Molecular Profiling |
| Molecular Profiling109 |
| Molecular Profiling |

| DNA Genotek's ORAcollectDx Collection Device ReceirFDA 510(k) Clearance | |
|---|---|
| deCODE Genetics Discovers Rare Variation In The | |
| Sequence Of The Human GenomeQIAGEN NV Unveils Targeted RNA Panels for Next- | 11 |
| Generation Sequencing | 11 |
| National Reference Laboratory and LabCorp Develop World-Class Assays for Personalized Medicine | 11 |
| 5. GLOBAL MARKET OVERVIEW | |
| 5.1 Global Personalized Medicine Market Overvie | |
| by Product Type | |
| Overview by Global Region | |
| 5.1.1.1 Personalized Medicine Diagnostics | |
| 5.1.1.2 Personalized Medical Care | |
| 5.1.1.4 Personalized Nutrition & Wellness | |
| 5.2 Global Personalized Medicine Market Overvie | |
| by Technology | 130 |
| 5.2.1 Personalized Medicine Technology Market Overview by Global Region | 121 |
| 5.2.1.1 Pharmacogenomics | |
| 5.2.1.2 Point-of-Care Testing | |
| 5.2.1.3 Stem Cell Therapy | |
| 5.2.1.4 Pharmacoproteomics | |
| 5.2.1.6 Other Technologies | |
| 5.3 Global Personalized Medicine Market Overvie | |
| by Application | . 144 |
| 5.3.1 Personalized Medicine Application Market Overview by Global Region | 146 |
| 5.3.1.1 Oncology | |
| 5.3.1.2 Central Nervous System (CNS) | |
| 5.3.1.3 Immunology | |
| | . TO |
| 5.3.1.5 Other Applications | |
| 5.3.1.5 Other Applications PART B: REGIONAL MARKET PERSPECTIVE | 154 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | 154 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | . 154 . 156 . 158 . 158 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | . 154 . 156 . 158 . 158 et |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | . 154 . 156 . 158 . 158 et |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | . 154 . 156 . 158 et . 158 et . 160 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | . 154 . 158 . 158 . 158 . 158 . 160 . 160 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | . 154 . 156 . 158 et . 158 et . 160 et . 160 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | .154 .158 .158 et . 158 et . 160 et . 160 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | . 154 . 158 . 158 et . 158 et . 160 et . 164 . 164 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | . 154 . 158 . 158 et . 160 et . 162 et . 164 . 166 . 166 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | 154 156 . 158 et . 158 et . 160 et . 166 . 166 . 166 . 166 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | . 154 . 156 . 158 et . 158 et . 166 et . 166 . 166 169 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | . 154 . 158 . 158 et . 160 et . 166 166 166 167 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | 154 .158 et .158 et .160 et .162 et .164 .164 .165 .173 .174 .175 .175 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | . 154 . 158 . 158 et . 158 et . 166 et . 166 166 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | 154 .158 et .158 et .160 et .160 .170 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | 154 .158 et .158 et .160 et .160 .170 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | . 154 . 158 et . 158 et . 160 et . 162 et . 164 . 164 . 164 . 17 . 17 . 17 . 17 . 17 . 18 . 18 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | 154 156 158 21 158 21 158 21 160 21 160 21 160 21 17 17 17 17 17 17 17 17 17 1 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | 154 156 158 21 160 21 160 21 160 21 160 21 17 17 17 17 17 17 17 17 17 1 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | 154 156 158 21 160 21 160 21 160 21 160 21 17 17 17 17 17 17 17 17 17 1 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | . 154 . 156 . 158 et . 166 et . 166 . 166 166 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | 154 156 158 21 160 21 160 21 160 21 160 21 17 17 17 17 17 17 17 17 17 1 |
| PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW | . 154 . 156 . 158 et . 158 et . 166 et . 166 167 179 179 179 188 |

| Illumina, Inc. (United States) | 196 |
|--|------|
| Ingenuity Systems, Inc. (United States) | 198 |
| Johnson & Johnson (United States) | |
| Laboratory Corporation of America (United States) . Luminex Corporation (United States) | |
| Millennium Health, LLC. (United States) | |
| Mylan, N.V (United States) | |
| Myriad Genetics, Inc. (United States) | |
| Nanostring Technologies, Inc. (United States) | |
| Perkinelmer, Inc. (United States) | |
| Pfizer, Inc. (United States) | |
| Precision Biologics, Inc. (United States) | |
| Promega Corporation (United States) | 214 |
| Roche Diagnostics Corporation (United States) | |
| Siemens Healthcare Diagnostics, Inc. (United States) | |
| Sigma-Aldrich Corporation (United States) | |
| Life Technologies Corporation (United States) | |
| 6.6 Country-wise Analysis of North American | |
| Personalized Medicine Market | 221 |
| 6.6.1 The United States | |
| 6.6.1.1 United States Personalized Medicine Ma | |
| Overview by Product Type | |
| 6.6.1.2 United States Personalized Medicine Ma | |
| Overview by Technology | 223 |
| 6.6.1.3 United States Personalized Medicine Ma | rket |
| Overview by Application | 225 |
| 6.6.2 Canada | 227 |
| 6.6.2.1 Canadian Personalized Medicine Market | |
| Overview by Product Type | 227 |
| 6.6.2.2 Canadian Personalized Medicine Market | |
| Overview by Technology | |
| 6.6.2.3 Canadian Personalized Medicine Market | |
| Overview by Application | 231 |
| 6.6.3 Mexico | 233 |
| 6.6.3.1 Mexican Personalized Medicine Market | |
| Overview by Product Type | 233 |
| 6.6.3.2 Mexican Personalized Medicine Market | |
| Overview by Technology | 235 |
| 6.6.3.3 Mexican Personalized Medicine Market | |
| Overview by Application | 237 |
| 7. EUROPE | 239 |
| 7.1 European Personalized Medicine Market | |
| Overview by Geographic Region | 239 |
| 7.2 European Personalized Medicine Market | |
| Overview by Product Type | 241 |
| 7.3 European Personalized Medicine Market | |
| Overview by Technology | 243 |
| 7.4 European Personalized Medicine Market | 245 |
| Overview by Application | |
| 7.5 Major Market Players Agendia B.V. (The Netherlands) | |
| Astrazeneca Plc (United Kingdom) | |
| Bayer AG (Germany) | |
| Bayer Healthcare Pharmaceuticals (Germany) | 253 |
| Biocartis NV (Belgium) | |
| Boehringer Ingelheim GmbH (Germany) | |
| Cytolon AG (Germany) Dako A/S (Denmark) | |
| Decode Genetics (Iceland) | |
| Eagle Genomics Ltd. (United Kindom) | 261 |
| Evotec AG (Germany) | |
| GE Healthcare Ltd. (United Kingdom) | |
| GlaxoSmithKline Plc (United Kingdom) Intomics A/S (Denmark) | |
| Medtronic Plc (Ireland) | |
| Merck KGAa (Germany) | 268 |
| Novartis AG (Switzerland) | |
| Novo Nordisk A/S (Denmark) | |
| Qiagen N.V. (The Netherlands) Roche Holding AG (Switzerland) | |
| NOVE HOUSE AN ENVIRENMENT | 414 |



Global Personalized Medicine Market – Types, Technologies and Applications October 2018 | 386 Pages | 171 Charts | Price \$4050

| Siemens AG (Germany) |
|---|
| 7.6 Country-wise Analysis of European Personalized Medicine Market |
| Overview by Product Type |
| 7.6.2 The United Kingdom |
| Market Overview by Product Type |
| 7.6.2.3 United Kingdom Personalized Medicine Market Overview by Application |
| 7.6.3.1 French Personalized Medicine Market Overview by Product Type292 7.6.3.2 French Personalized Medicine Market |
| Overview by Technology |
| 7.6.4 Italy |
| Overview by Product Type |
| 7.6.4.3 Italian Personalized Medicine Market Overview by Application |
| 7.6.5 Rest of Europe |
| 7.6.5.2 Rest of European Personalized Medicine Market Overview by Technology |
| Market Overview by Application |
| Overview by Geographic Region |

| 8.3 Asia-Pacific Personalized Medicine Market |
|--|
| Overview by Technology314 |
| 8.4 Asia-Pacific Personalized Medicine Market |
| Overview by Application316 |
| 8.5 Major Market Players 318 |
| Astellas Pharma, Inc. (Japan)318 |
| Daiichi Sankyo Company Limited (Japan) |
| Mitsubishi Tanabe Pharma Corporation (Japan)320 |
| Takeda Pharmaceutical Company Limited (Japan) 321 |
| 8.6 Country-wise Analysis of Asia-Pacific Personalized |
| Medicine Market 322 |
| 8.6.1 Japan322 |
| 8.6.1.1 Japanese Personalized Medicine Market |
| Overview by Product Type322 |
| 8.6.1.2 Japanese Personalized Medicine Market |
| Overview by Technology324 |
| 8.6.1.3 Japanese Personalized Medicine Market |
| Overview by Application326 |
| 8.6.2 China328 |
| 8.6.2.1 Chinese Personalized Medicine Market |
| Overview by Product Type328 |
| 8.6.2.2 Chinese Personalized Medicine Market |
| Overview by Technology |
| 8.6.2.3 Chinese Personalized Medicine Market |
| Overview by Application |
| 8.6.3 India |
| 8.6.3.1 Indian Personalized Medicine Market |
| Overview by Product Type |
| 8.6.3.2 Indian Personalized Medicine Market |
| Overview by Technology |
| 8.6.3.3 Indian Personalized Medicine Market |
| Overview by Application |
| |
| 8.6.4 Rest of Asia-Pacific340 |
| 8.6.4.1 Rest of Asia-Pacific Personalized Medicine |
| Market Overview by Product Type 340 |
| 8.6.4.2 Rest of Asia-Pacific Personalized Medicine |
| Market Overview by Technology 342 |
| 8.6.4.3 Rest of Asia-Pacific Personalized Medicine |
| Market Overview by Application344 |
| 9. SOUTH AMERICA346 |
| 9.1 South American Personalized Medicine Market |
| Overview by Geographic Region |
| 9.2 South American Personalized Medicine Market |
| |
| Overview by Product Type348 |
| Overview by Product Type |
| Overview by Product Type |

| 9.4 South American Personalized Medicine Market Overview by Application | |
|--|------------|
| 9.5 Country-wise Analysis of South American Personalized Medicine Market | 354 |
| 9.5.1 Brazil | |
| 9.5.1.1 Brazilian Personalized Medicine Market Overview by Product Type | 354 |
| Overview by Technology | |
| Overview by Application | |
| 9.5.2.1 Argentinean Personalized Medicine Market | |
| Overview by Product Type | |
| 9.5.2.3 Argentinean Personalized Medicine Market Overview by Application | |
| , | |
| 9.5.3 Rest of South America | ine |
| Market Overview by Product Type | |
| Market Overview by Technology | |
| 9.5.3.3 Rest of South American Personalized Medic | |
| Market Overview by Application | 370 |
| 10. REST OF WORLD | 372 |
| 10.1 Rest of World Personalized Medicine Market | |
| Overview by Product Type | 372 |
| Overview by Technology | 374 |
| 10.3 Rest of World Personalized Medicine Market | |
| Overview by Application | |
| 10.4 Major Market Players | |
| Rosetta Genomics Ltd. (Israel) TEVA Pharmaceutical Industries Ltd. (Israel) | |
| PART C: GUIDE TO THE INDUSTRY3 | 8 0 |
| 1. NORTH AMERICA | |
| 2. EUROPE | |
| 3. ASIA-PACIFIC | |
| 4. REST OF WORLD | 384 |
| PART D: ANNEXURE3 | |
| 1. RESEARCH METHODOLOGY | |
| 2. FEEDBACK | 387 |



About Industry Experts

Industry Experts' market research, backed by years of experience and an analytical team dedicated to providing the most optimal business solutions, has been specifically designed to provide a variety of benefits, both current and future. Our leading-edge publications make the life easy for corporate strategists, investors, analysts and researchers, startups, consultants, financial and banking executives, academicians and many more. The company also provides customized research reports to cater the needs of the industry.

Business intelligence provides the critical link between comprehending prevailing market conditions and devising strategies to maximize parameters, such as revenues, profits and return on investment in order to gain market share. The significance of market research can be largely understood through the range of factors that impact businesses. These can comprise market size (current and projected), geographic market reach and demand and supply scenario, to name a few. Our ongoing quest to collect up to date and accurate information by conducting online surveys, personal interviews, taking the opinions of senior level executives will enable us to serve our clients better in every possible aspect.

More about Industry Experts



Industry Experts, Inc.

14726 Ramona Ave, Suite S2 Chino, CA 91710 Greater Los Angeles United States

Phone: +1-320-iXPERTS (497-3787)

Email: info@industry-experts.com

India Office

1-7-19/C, Street No. 8, Habsiguda Hyderabad – 500007 India

Phone: +91-40-4018-1314 Fax: +91-40-2715-7746

Website: http://industry-experts.com